Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
8.9 USD | +3.25% | +14.10% | +505.44% |
Kurzporträt
Mitarbeiterzahl: 42
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 01.09.20 |
Founder | 66 | 01.01.02 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
Seshu Tyagarajan
CTO | Chief Tech/Sci/R&D Officer | 57 | 02.03.22 |
Francesca Barone
CTO | Chief Tech/Sci/R&D Officer | 47 | 01.11.20 |
William Nichols
CTO | Chief Tech/Sci/R&D Officer | 55 | 12.09.22 |
Ileen B. Winick
HRO | Human Resources Officer | - | 01.01.21 |
Nathan Caffo
PRN | Corporate Officer/Principal | 55 | 01.09.20 |
Susan Stewart
LAW | General Counsel | 64 | 01.10.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 08.08.22 |
Edward Benz
BRD | Director/Board Member | 78 | 01.09.17 |
Paul Manning
CHM | Chairman | 68 | 01.11.18 |
Gary Nabel
BRD | Director/Board Member | 70 | 08.08.22 |
Founder | 66 | 01.01.02 | |
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 01.09.20 |
Renee Gaeta
BRD | Director/Board Member | 42 | 08.08.22 |
Diem Nguyen
BRD | Director/Board Member | 52 | 15.07.21 |
Director/Board Member | 45 | 01.11.18 | |
Nicoletta Loggia
BRD | Director/Board Member | - | 07.06.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 29 878 613 | 20 005 186 ( 66,95 %) | 122 608 ( 0,4104 %) | 66,95 % |
Unternehmenskontakt
Sektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+505.44% | 265 Mio. | |
+43.36% | 54.63 Mrd. | |
-5.31% | 39.92 Mrd. | |
+14.75% | 26.86 Mrd. | |
-12.56% | 26.22 Mrd. | |
-22.45% | 18.78 Mrd. | |
+25.12% | 12.21 Mrd. | |
+0.04% | 12.16 Mrd. | |
+26.04% | 11.94 Mrd. | |
-11.83% | 10.74 Mrd. |
- Börse
- Aktien
- A3CVW2 Aktie
- Unternehmen Candel Therapeutics, Inc.